Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Acute myelogenous leukemia, or AML, is a type of blood cancer. It is a quickly progressing disease in which too many abnormal white blood cells are found in the bone marrow, the soft, spongy center of long bones.
In AML, myeloid stem cells (a type of blood stem cell) become immature white blood cells called myeloblasts or “blasts.” These blasts do not become healthy white blood cells. Instead, they build up in the bone marrow, so there is less room for healthy white blood cells, red blood cells, and platelets. In addition, these abnormal cells are unable to fight off infection.
Children with acute myelogenous leukemia are treated at Dana-Farber/Boston Children's through our Leukemia Program. Dana-Farber/Boston Children's has played a key role in refining treatment for childhood leukemia, and we continue to be a world leader in leukemia clinical trials designed to increase cure rates, decrease treatment-related side effects and improve care for long-term survivors.
The Leukemia Program also partners closely with Dana-Farber/Boston Children's Stem Cell Transplant Center, one of the most experienced stem cell transplant centers in the world, when stem cell transplant is recommended for your child's care.
Find in-depth information on acute myelogenous leukemia (AML) on the Dana-Farber/Boston Children's website, including answers to:
Appointments and Second Opinions